Sentence examples for received mood from inspiring English sources

A substantial number of patients with schizophrenia received mood stabilisers and/or antidepressants in addition to their main antipsychotic therapy.

One (6.3%) attempter and 3 (7.7%) non-attempters received mood stabilizer (p = ns).. Six (37.5%) attempters and 8 (20.5%) received antipsychotic medication (p = ns).

Likewise, in patients with BD, a wide variety of antipsychotic medications were used, employed in various combinations and many also received mood stabilisers and/or antidepressants.

In patients with schizophrenia, ~1/3 of patients receiving antipsychotic monotherapy also received mood stabilisers and/or antidepressants (34.7%) compared with over half of those on antipsychotic polytherapy (52.2%).

In patients with BD, use of mood stabilisers and/or antidepressants was even higher; 76.9% of patients receiving antipsychotic monotherapy also received mood stabilisers and/or antidepressants compared with 85.5% of patients on antipsychotic polytherapy.

Patients with BD receiving antipsychotic polytherapy were also more likely to receive other therapies such as mood stabilisers and/or antidepressants than those receiving antipsychotic monotherapy; in patients treated with polytherapy, 85.5% received mood stabilisers and/or antidepressants compared with only 76.9% treated with antipsychotic monotherapy.

Although Fig. 1 indicates a fairly good spread of data, low serum concentrations in these groups might have limited the ability to uncover significant associations, and possibly also the relevance to a broader population receiving mood stabilizers.

All BD participants were receiving mood stabilizers, 8 of which were receiving lithium.

Medication treatment patterns are variable in the acute and long-term management of bipolar disorder, with 42-64% of patients receiving mood stabilizers, such as lithium, valproate or carbamazapine, and 44-60% receiving adjunctive antipsychotics [ 4- 6].

4 Similarly, in the STEP-BD trial, 42 of 179 subjects (23.5%) receiving a mood stabiliser plus adjunctive antidepressant drug treatment had a durable recovery, which did not differ significantly from 51 of 187 subjects (27.3%) receiving mood stabiliser plus placebo.

We then redefined our group variable to include 2 subgroups: subjects receiving mood-stabilizers (n = 16; 10 bipolar, 3 depressed, 3 schizophrenics) and subjects not receiving mood-stabilizers (n = 44), again there was no significant difference between groups in both mRNA and protein of all three subunits in the two brain areas.